Mineralys Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 18.18 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.61B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Minera...